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Azacitidine (AZA) improves long-term outcomes of higher-risk MDS
patients and is now the reference frontline therapy of higher-risk MDS
not eligible for allogeneic stem cell transplant. Anaemia is the most com-
mon symptom of MDS and most patients become transfusion-depen-
dent with the risk of iron overload. Deferasirox is an orally available
iron chelator administered once-daily in transfusion-dependent patients
with iron overload. We report our experience on using the azacitidine
in patients with high-risk MDS, evaluating the efficacy and safety. Con-
comitant treatment with deferasirox was performed in a routine clinical
setting following Consensus Guidelines on Iron Chelation Therapy. In
our Institution from October 2009 to December 2014 we have treated
29 elderly patients (19 male and 10 female, median age 76 years, r. 72-
88) affected by HIGH-RISK MDS (IPSS INT-2/HIGH). Patients received
subcutaneous azacitidine at 75mg/m(2) daily for 7 days every 4 weeks.
All patients completed at least 6 cycles of therapy. 11/29 (38%) patients
underwent more than 8 cycles of therapy. 17/29 patients underwent as
well iron chelation therapy with deferasirox receiving a starting dosage
of 10 mg/kg/day, subsequently titrated according to serum ferritin (SF)
measured monthly. Complete response (CR), partial response (PR), and
hematologic improvement (HI) were observed in 2 (7%), 5 (21%), and
11 (38%) patients, respectively. The median number of cycles to clinical
response was 4 (range 4-8). The 2-year rate of acute myeloid leukemia-
free survival was 48%. Five serious adverse events occurred in five pa-
tients with one fatal outcome. 15 out of 18 patients who showed any
hematologic response (CR+PR+HI) meeting International Working
Group 2006 criteria had also performed deferasirox therapy. No in-
creased toxicity was noted when deferasirox was used concomitantly
with azacitidine. Our results confirm the effectiveness of the therapy
with azacitidine in HIGH-RISK MDS elderly patients with acceptable
toxicity profile. Peripheral cytopenias were the most commonly occur-
ring adverse event, with gastrointestinal adverse events and injection-
site reactions among the most commonly occurring non-haematological
adverse events. In conclusion, azacitidine is an important agent for use
in the treatment of elderly patients with MDS. Furthermore concurrent
use of deferasirox in patients with iron overload seems to significantly
improve the hematologic response by reducing transfusion requirement. 
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Background: Anemia is the most frequent cytopenia in Myelodysplas-
tic Syndrome (MDS). Epoetin a, Epoetin b and Darbepoetin a (ESA)
have been investigated in several studies as useful to treat anemia in this
category of patients.Available pre-clinical data support oxidative stress
and hemolysis contributing to ESA resistance but not clinical data is
today available. G6PD deficiency is an X-linked condition characterized
by a markedly reduced capability to protect red blood cells from oxida-
tive stresses. In the island of Sardinia the prevalence is reported to be as
high as 12%. Patients and Methods:We retrospectively analyzed all MDS
patients who had received ESA in our centre. Diagnosis of MDS was
made according to WHO criteria. Patients were stratified based on In-
ternational Prognostic Scoring System (IPSS). At diagnosis baseline EPO
level and G6PD quantitative estimation were detected. Red blood cell
(RBC) transfusions requirement before starting treatment was evaluated.
Erythroid hematologic improvement (HI-E) was evaluated according to
the International Working Group (IWG) response criteria (Cheson et al.
JCO 2006). Results: Thirty patients met the above specified criteria. Of
them 7 were G6PD-defiecient and 23 had normal G6PD level values.
Seventeen were male and 13 female, median age was 71 years (range
51-96). Twenty patients presented with refractory anemia (RA), 8 re-
fractory anemia with ringed sideroblasts (RARS), 2 refractory cytopenias
with multilineage dysplasia (RMCD). Twenty-four patients were IPSS
low- risk and 6 Intermediate I. At baseline serum EPO level was less
then 200 IU/L in all patients. Forty percent required RBC transfusion be-
fore starting ESA treatments. Twenty patients (80%) achieved an HI-E
(14 major and 10 minor). In the G6PD-deficient group HI-E was ob-
served in 7 over 7 patients (major in 4 and minor in 3). In the control
group HI-E was observed in 17 over 23 patients (major in 10 minor in
7). (P=0.29). Conclusions:We evaluated 30 MDS low- risk and Int I IPSS
patients who received ESA in the last 20 years in our centre. Despite the
common belief that oxidative stress and hemolysis may contribute to
ESA resistance, no statistically significant difference to potentially re-
sistance to ESA treatment in G6PD deficiency have been observed. We
conclude that G6PD-deficiency does not contraindicate the use of ESA
in this setting of patients.
Table 1. Patients’ characteristics.
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The myelodysplastic syndromes (MDS) are heterogeneous
hematopoietic diseases associated with bone marrow failure, periph-
eral cytopenias, and a tendency to progress to acute myeloid
leukemia. Anemia and transfusion dependency constitute major prob-
lems for MDS patients. Treatment with erythropoiesis stimulating
agents is a first-line treatment for the anemia of most patients with
MDS. However not all MDS respond and a majority of patients even-
tually relapse with transfusion dependent anemia. Erythropoietin
(Epo) is the principal regulator of red blood cell production. Upon Epo
binding to its cognate receptor (R), the Epo-R promote the activation
of JAK2 and Lyn, which in turn phosphorylate the signal transducer
and activator of transcription 5 (STAT5). Dimerization of phospho (P)-
STAT5 enables its translocation to the nucleus and binding to target
gene promoters, ultimately promoting the expansion, differentiation,
and survival of red blood cell precursors. Transferrin receptor 2 (TFR2)
is a second transferrin (Tf) receptor that binds to Tf with a 25-fold
lower affinity but acts as an iron sensor regulating hepatic hepcidin
production. At least 2 alternatively spliced forms of transcripts, a and
b, are transcribed from the TFR2 gene. Several recent findings (Fore-
jtnikova et al., Blood 2010; Wallace et al., Br J Haematol. 2015; Nai et
al., Blood 2015) highlight the interconnection between the hepatic
and erythroid functions of TFR2 in regulating iron metabolism and
erythropoiesis. Our monocentric and retrospective study aimed to
identify the possible impact of TFR2 and EpoR mRNA expression at
diagnosis in MDS patients. We report the expression pattern of TFR2
a, b and EpoR in various subtype of MDS in comparison to normal
controls and we found heterogeneous expression with a tendency of
TFR2 being less expressed in RAEB-2. Moreover a positive and signif-
icant correlation between TFR2 and EpoR expression was seen. Fi-
nally, to further assess the clinical implication of the correlation
observed, we analysed the erythroid response in the cohort of patients
that underwent to Epo treatment and we noticed that only patients
with TFR2 and EpoR levels comparable to normal controls reached
an increase in hemoglobin level of ≥1.5 g/dl after 12 weeks of treat-
ment. Taken together, our results provide evidence suggesting TFR2
and EpoR as potential molecular markers in predicting at diagnosis
the response of Epo treatment in MDS patients.
104 | haematologica| 2015; 100(s3)
2015_SIE_ok.qxp_Layout 1  22/09/15  12:36  Pagina 104
